Keyphrases
Activity Level
12%
Advanced Prostate Cancer
100%
Agonist Treatment
12%
Antigen Levels
12%
Cardiovascular Effects
12%
Clinical Indications
12%
Fibrinolytic Parameters
25%
Fibrinolytic System
12%
First Dose
12%
Gonadotropin-releasing Hormone
100%
Goserelin Acetate
25%
Inhibitor Activity
12%
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
37%
Molar Ratio
12%
Plasma Tissue
12%
Plasminogen Activator inhibitor-1 (PAI-1)
50%
Prostate Radiotherapy
12%
Prostate-specific Antigen Level
12%
Short-term Effects
100%
Subcutaneous Administration
12%
Thrombin-activatable Fibrinolysis Inhibitor
25%
Tissue Plasminogen Activator (t-PA)
50%
Total Prostate-specific Antigen
12%
Zoladex
12%
Pharmacology, Toxicology and Pharmaceutical Science
Fibrinolytic Agent
100%
Gonadorelin Agonist
100%
Goserelin
37%
Plasminogen Activator Inhibitor
12%
Prostate Cancer
100%
Prostate Specific Antigen
12%
Subcutaneous Injection
12%
Thrombin Activatable Fibrinolysis Inhibitor
25%
Tissue Plasminogen Activator
50%